Where does Atai Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Atai Therapeutics, Inc. ranks #23,918 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Atai Therapeutics, Inc. hold?

Atai Therapeutics, Inc. holds 11 US utility patents granted between 2024 and 2025, spanning 10 technology areas.

What is Atai Therapeutics, Inc.'s Innovation Score?

Atai Therapeutics, Inc. has an Innovation Score of 51.9 out of 100 (top 11% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Atai Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Atai Therapeutics, Inc..

What does claim depth mean for Atai Therapeutics, Inc.'s patents?

Atai Therapeutics, Inc.'s patents average 20.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Atai Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Atai Therapeutics, Inc.

Q: What technology areas does Atai Therapeutics, Inc. focus on?

Atai Therapeutics, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 5 patents. Grants appear in 10 CPC subclasses total.

USPTO PatentsView assignee record - 11 granted patents across 10 technology areas, recorded in grant years 2024–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Atai ranks #23,918 of 50,000 tracked US assignees by granted-patent volume, with 11 patents across 10 technology areas.

#23,918
of 50,000 US assignees by volume: Top 11%
by Innovation Score (51.9/100): 20.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R23918 · US Corporation #23,918 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 11 grants
MID-PACK #23,918/50,000
PHOTO-FINISH Ashwin-Ushas
CPC-FOCUS A61P · 10 areas
INNOV-PAR 51.9/100
CLAIMS-DENSE 20.2 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2024–2025 · 2y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Ashwin-ushas Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Atai Therapeutics · this assignee

52
3D Lighting Innovati… · lowest

7

What this shows Atai's Innovation Score is 51.9/100 (top 11% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Atai's grants concentrate

Atai Therapeutics, Inc. is a focused PatentsView assignee: 10 CPC subclasses with 45.5% of grants classified under A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). By volume, Atai sits between Ashwin-ushas Corporation and Audyssey Laboratories, Inc..

Atai's three-year grant acceleration

Atai Therapeutics, Inc. shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Ashwin-ushas

11
Assurant Design A…

11
Asurion

11
Asyst L L C

11
Ateliers Busch

11
Athena Club Holdi…

11
Athletic Propulsi…

11
Audyssey Laborato…

11
Atai Therapeutics ◀

11

What this shows Atai holds 11 patents at rank #23,934, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Atai

By rank, the assignees closest to #23,934 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Atai's primary technology class.

Atai's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

52 Top 11% higher than 89% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2024–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.

View data table

Atai Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2024	6	54.5%
2025partial year	5	45.5%

Which technologies does Atai Therapeutics, Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 5

C07D - HETEROCYCLIC COMPOUNDS 5

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 4

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 3

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 2

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 1

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 1

G06F - ELECTRIC DIGITAL DATA PROCESSING 1

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 1

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 1

Top 10 of 10 technology areas

Where it ranks

Overall rank by patents

#23,918

of 50,000 tracked assignees

Innovation Score

51.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.